...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Rheumatology >Resolution of calcinosis using bisphosphonates in overlap syndrome – a case report
【24h】

Resolution of calcinosis using bisphosphonates in overlap syndrome – a case report

机译：使用双膦酸盐综合征使用双膦酸盐分辨率分辨率 - 案例报告

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Calcinosis cutis is a common complication of pediatric rheumatologic diseases. However, there is currently no consensus on first-line treatment. Bisphosphonates have been described as a successful treatment in several case studies, but most of these cases are limited to patients with isolated juvenile dermatomyositis or systemic sclerosis. Specifically, there are limited reports of their usefulness in treating overlap syndromes and mixed connective tissue disorders. We describe the case of a 13?year-old girl with overlap syndrome with features of juvenile dermatomyositis and systemic lupus erythematosus. After 22?months of extensive immunosuppressive therapy, including monthly IVIG and Rituximab, she continued to have pain and weakness of the lower extremities. A CT scan was performed which showed significant multifocal soft tissue calcifications of the pelvis. She was started on treatment with oral alendronate with the goal of improving her calcinosis and improving her symptoms. After several months of therapy, our patient reported subjective improvement of her lower extremity pain and weakness, as well as complete resolution of abnormalities previously seen on physical examination. A repeat CT scan of the pelvis was performed after 11?months of therapy and demonstrated complete resolution of the previously seen calcinosis. We report the successful treatment of soft tissue calcinosis with oral bisphosphonates in a patient with juvenile dermatomyositis-systemic lupus erythematosus overlap syndrome. These results provide further evidence that bisphosphonates can be used successfully to treat calcinosis cutis in pediatric rheumatologic disorders. Additionally, the results provide new evidence that they can be used specifically in juvenile dermatomyositis-systemic lupus erythematosus overlap syndrome, which has not been previously reported.
机译：钙蛋白切割是儿科风湿病疾病的常见并发症。但是，目前没有关于一线治疗的共识。双膦酸盐已被描述为几种案例研究中的成功治疗，但大多数这些病例仅限于患有孤立的少年皮肤病或全身硬化的患者。具体而言，它们在治疗重叠综合征和混合结缔组织疾病方面的有用性有限的报道。我们描述了一个13的案例？岁月的患者，具有重叠综合征，具有少年皮质肌和系统性红斑狼疮的特征。在22岁以下？几个月的广泛免疫抑制治疗，包括每月IVIG和Rituximab，她继续患有下肢的疼痛和弱点。进行CT扫描，其显示出骨盆的显着多焦点软组织钙化。她开始用口服alendronate进行治疗，目标是改善她的辅病症并改善症状。经过几个月的治疗后，我们的患者报告了她的下肢疼痛和弱点的主观改善，以及完全解决以前在体检中看到的异常。骨盆的重复CT扫描在11个月的治疗后进行，并证明了先前看到的钙化的完全分辨率。我们报告了用幼年皮肤病 - 全身性狼疮性红斑狼疮患者口服双膦酸盐的软组织溶质的成功治疗。这些结果提供了进一步的证据，即双膦酸盐可以成功地用于治疗儿科风湿病病毒疾病的辅病虫松。此外，结果提供了新的证据，即它们可以特别用于少年皮质肌炎 - 全身性红斑狼疮重叠综合征，其尚未报道。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号